LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 24

Search options

  1. Article ; Online: An acceptance-based, intersectional stigma coping intervention for people with HIV who inject drugs-a randomized clinical trial.

    Luoma, Jason B / Rossi, Sarah L / Sereda, Yuliia / Pavlov, Nikolai / Toussova, Olga / Vetrova, Marina / Bendiks, Sally / Kiriazova, Tetiana / Krupitsky, Evgeny / Lioznov, Dmitry / Blokhina, Elena / Lodi, Sara / Lunze, Karsten

    The Lancet regional health. Europe

    2023  Volume 28, Page(s) 100611

    Abstract: Background: People with HIV who inject drugs experience intersecting forms of stigma that adversely impact care access. This RCT aimed to evaluate effects of a behavioral intersectional stigma coping intervention on stigma and care utilization.: ... ...

    Abstract Background: People with HIV who inject drugs experience intersecting forms of stigma that adversely impact care access. This RCT aimed to evaluate effects of a behavioral intersectional stigma coping intervention on stigma and care utilization.
    Methods: We recruited 100 participants with HIV and past-30-day injection drug use at a non-governmental harm reduction organization in St. Petersburg, Russia, and randomized them 1:2 to receive usual services only or an additional intervention of three weekly 2-h group sessions. Primary outcomes were change in HIV and substance use stigma scores at one month after randomization. Secondary outcomes were initiation of antiretroviral treatment (ART), substance use care utilization, and changes in frequency of past-30-days drug injection at six months. The trial was registered as NCT03695393 at clinicaltrials.gov.
    Findings: Participant median age was 38.1 years, 49% were female. Comparing 67 intervention and 33 control group participants recruited October 2019-September 2020, the adjusted mean difference (AMD) in change in HIV and substance use stigma scores one month after baseline were 0.40, (95% CI: -0.14 to 0.93, p = 0.14) and -2.18 (95% CI: -4.87 to 0.52, p = 0.11), respectively. More intervention participants than control participants initiated ART (n = 13, 20% vs n = 1, 3%, proportion difference 0.17, 95% CI: 0.05-0.29, p = 0.01) and utilized substance use care (n = 15, 23% vs n = 2, 6%, proportion difference 0.17, 95% CI: 0.03-0.31, p = 0.02). The adjusted median difference in change in injecting drug use frequency 6 months after baseline was -3.33, 95% CI: -8.51 to 1.84, p = 0.21). Five not intervention-related serious adverse events (7.5%) occurred in the intervention group, one (3.0%) serious adverse event in the control group.
    Interpretation: This brief stigma-coping intervention did not change stigma manifestations or drug use behaviors in people with HIV and injection drug use. However, it seemed to reduce stigma's impact as an HIV and substance use care barrier.
    Funding: R00DA041245, K99DA041245, P30AI042853.
    Language English
    Publishing date 2023-03-20
    Publishing country England
    Document type Journal Article
    ISSN 2666-7762
    ISSN (online) 2666-7762
    DOI 10.1016/j.lanepe.2023.100611
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Addressing intersectional stigma as a care barrier for HIV-positive people who inject drugs: Design of an RCT in St. Petersburg, Russia.

    Rossi, Sarah L / Sereda, Yuliia / Luoma, Jason B / Pavlov, Nikolai / Toussova, Olga / Vasileva, Janna / Abramova, Kristina / Bendiks, Sally / Kiriazova, Tetiana / Vetrova, Marina / Blokhina, Elena / Krupitsky, Evgeny / Lioznov, Dmitry / Lodi, Sara / Lunze, Karsten

    Contemporary clinical trials communications

    2021  Volume 24, Page(s) 100861

    Abstract: Background: HIV-positive people who inject drugs (PWID) experience stigma related to their substance use and HIV, with adverse consequences to their health care utilization and mental health. To help affected individuals cope with their intersectional ... ...

    Abstract Background: HIV-positive people who inject drugs (PWID) experience stigma related to their substance use and HIV, with adverse consequences to their health care utilization and mental health. To help affected individuals cope with their intersectional stigma and reduce its negative impact on health and health care, we adapted a behavioral stigma coping intervention for this HIV key population.
    Objective: To conduct a randomized controlled trial (RCT) testing the 'Stigma Coping to Reduce HIV risks and Improve substance use Prevention and Treatment' (SCRIPT) intervention, a community-based, adapted form of Acceptance and Commitment Therapy (ACT), for PWID living with HIV in St. Petersburg, Russia.
    Methods: We recruited 100 PWID living with HIV from civil society organizations (CSO) delivering harm reduction and HIV prevention services in St. Petersburg, Russia. We randomized participants 2:1 to receive either the intervention (three adapted ACT sessions in a group format over one month and usual CSO care) or usual CSO care alone. ACT aims to help affected individuals cope with stigma by increasing their psychological flexibility to handle stigma-related negative expectations, emotions and experiences. The primary outcomes were satisfaction with the intervention, and changes in HIV and substance use stigma scores.
    Conclusions: Stigma coping interventions targeting HIV-positive PWID outside of formal health care settings may help them confront negativities in their lives originating from intersectional stigma and reduce stigma's impact as a health care barrier.
    Language English
    Publishing date 2021-11-19
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2451-8654
    ISSN (online) 2451-8654
    DOI 10.1016/j.conctc.2021.100861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Treatment of COVID‐19 patients with a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation

    Khaitov, Musa / Nikonova, Alexandra / Kofiadi, Ilya / Shilovskiy, Igor / Smirnov, Valeriy / Elisytina, Olga / Maerle, Artem / Shatilov, Artem / Shatilova, Anastasia / Andreev, Sergey / Sergeev, Ilya / Trofimov, D. / Latysheva, Tatyana / Ilyna, Natalia / Martynov, Alexander / Rabdano, Sevastyan / Ruzanova, Ellina / Savelev, Nikita / Pletiukhina, Iuliia /
    Safi, Ariana / Ratnikov, Vyacheslav / Gorelov, Viktor / Kaschenko, Viktor / Kucherenko, Natalya / Umarova, Irina / Moskaleva, Svetlana / Fabrichnikov, Sergei / Zuev, Oleg / Pavlov, Nikolai / Kruchko, Daria / Berzin, Igor / Goryachev, Dmitriy / Merkulov, Vadim / Shipulin, German / Udin, Sergey / Trukhin, Victor / Valenta, Rudolf / Skvortsova, Veronica

    Allergy. 2023 June, v. 78, no. 6, p. 1639-1653

    2023  , Page(s) 1639–1653

    Abstract: BACKGROUND: Severe acute respiratory syndrome corona virus (SARS‐CoV‐2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS‐CoV‐2‐specific siRNA‐ ... ...

    Abstract BACKGROUND: Severe acute respiratory syndrome corona virus (SARS‐CoV‐2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation MIR 19® (siR‐7‐EM/KK‐46) targeting a conserved sequence in known SARS‐CoV‐2 variants for treatment of COVID‐19. METHODS: We conducted an open‐label, randomized, controlled multicenter phase II trial (NCT05184127) evaluating safety and efficacy of inhaled siR‐7‐EM/KK‐46 (3.7 mg and 11.1 mg/day: low and high dose, respectively) in comparison with standard etiotropic drug treatment (control group) in patients hospitalized with moderate COVID‐19 (N = 52 for each group). The primary endpoint was the time to clinical improvement according to predefined criteria within 14 days of randomization. RESULTS: Patients from the low‐dose group achieved the primary endpoint defined by simultaneous achievement of relief of fever, normalization of respiratory rate, reduction of coughing, and oxygen saturation of >95% for 48 h significantly earlier (median 6 days; 95% confidence interval [CI]: 5–7, HR 1.75, p = .0005) than patients from the control group (8 days; 95% CI: 7–10). No significant clinical efficacy was observed for the high‐dose group. Adverse events were reported in 26 (50.00%), 25 (48.08%), and 28 (53.85%) patients from the low‐, high‐dose and control group, respectively. None of them were associated with siR‐7‐EM/KK‐46. CONCLUSIONS: siR‐7‐EM/KK‐46, a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID‐19 compared to standard therapy in a randomized controlled trial.
    Keywords COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; confidence interval ; dendrimers ; drug therapy ; fever ; hypersensitivity ; oxygen ; randomized clinical trials ; respiratory rate ; viruses
    Language English
    Dates of publication 2023-06
    Size p. 1639-1653
    Publishing place John Wiley & Sons, Ltd
    Document type Article ; Online
    Note JOURNAL ARTICLE
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.15663
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  4. Article ; Online: Correction to: The epidemiology and management of odontomas: a European multicenter study.

    Boffano, Paolo / Cavarra, Francesco / Brucoli, Matteo / Ruslin, Muhammad / Forouzanfar, Tymour / Ridwan-Pramana, Angela / Rodríguez-Santamarta, Tanía / de Vicente, Juan Carlos / Starch-Jensen, Thomas / Pechalova, Petia / Pavlov, Nikolai / Doykova, Iva / Konstantinovic, Vitomir S / Jezdić, Zoran / Barrabé, Aude / Louvrier, Aurélien / Meyer, Christophe / Snäll, Johanna / Hagström, Jaana /
    Dovšak, Tadej / Birk, Anže / Rocchetti, Vincenzo

    Oral and maxillofacial surgery

    2022  Volume 27, Issue 4, Page(s) 721

    Language English
    Publishing date 2022-08-08
    Publishing country Germany
    Document type Published Erratum
    ZDB-ID 2406731-3
    ISSN 1865-1569 ; 1865-1550
    ISSN (online) 1865-1569
    ISSN 1865-1550
    DOI 10.1007/s10006-022-01110-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The epidemiology and management of odontomas: a European multicenter study.

    Boffano, Paolo / Cavarra, Francesco / Brucoli, Matteo / Ruslin, Muhammad / Forouzanfar, Tymour / Ridwan-Pramana, Angela / Rodríguez-Santamarta, Tanía / de Vicente, Juan Carlos / Starch-Jensen, Thomas / Pechalova, Petia / Pavlov, Nikolai / Doykova, Iva / Konstantinovic, Vitomir S / Jezdić, Zoran / Barrabé, Aude / Louvrier, Aurélien / Meyer, Christophe / Snäll, Johanna / Hagström, Jaana /
    Dovšak, Tadej / Birk, Anže / Rocchetti, Vincenzo

    Oral and maxillofacial surgery

    2022  Volume 27, Issue 3, Page(s) 479–487

    Abstract: Introduction: Odontoma is the most commonly diagnosed odontogenic tumor of the oral cavity. The objective of the present study was to assess the demographic variables, patterns, diagnostic features, and management issues of odontomas treated at several ... ...

    Abstract Introduction: Odontoma is the most commonly diagnosed odontogenic tumor of the oral cavity. The objective of the present study was to assess the demographic variables, patterns, diagnostic features, and management issues of odontomas treated at several European departments of maxillofacial and oral surgery.
    Materials and methods: This study was conducted at 8 European departments of oral surgery between January 1, 2004, and December 31, 2018. Only patients with odontomas were included. The following data were recorded for each patient: gender, age, comorbidities, site, size of odontomas, radiographic features, type of odontoma, treatment of odontomas, treatment of associated teeth, complications, and recurrence.
    Results: A total of 127 patients (70 male and 57 female patients) with odontomas were included. The mean age was 22 years; 71 odontomas were found in the mandible, whereas 56 in the maxilla. In the mandible, the most frequently involved subsite was the parasymphysis, while in the maxilla, the most common subsite was the upper incisor region. The mean size of included odontomas was 15.3 mm. On the whole, 62 complex odontomas, 50 compound odontomas, and 15 mixed-type odontomas were observed. Complete excision of the odontomas was performed in 121 patients. In 24 patients, the extraction of deciduous teeth was performed, and in 43 patients, one or more permanent teeth were removed. Finally, in 9 patients, a partial excision of the odontoma was performed. Recurrence was observed in 4 cases out of 127 patients.
    Conclusions: Dental practitioners should be aware of the distinct clinical and radiographic features of odontoma in order to perform an appropriate and early diagnosis. Conventional radiography, such as panoramic radiograph, is often sufficient technique for a diagnosis after clinical suspicion or for an incidental diagnosis to prevent later complications, such as impaction or failure of eruption of teeth.
    MeSH term(s) Humans ; Male ; Female ; Young Adult ; Adult ; Odontoma/diagnostic imaging ; Odontoma/epidemiology ; Dentists ; Professional Role ; Tooth, Impacted/surgery ; Maxilla
    Language English
    Publishing date 2022-06-17
    Publishing country Germany
    Document type Multicenter Study ; Journal Article
    ZDB-ID 2406731-3
    ISSN 1865-1569 ; 1865-1550
    ISSN (online) 1865-1569
    ISSN 1865-1550
    DOI 10.1007/s10006-022-01091-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation.

    Khaitov, Musa / Nikonova, Alexandra / Kofiadi, Ilya / Shilovskiy, Igor / Smirnov, Valeriy / Elisytina, Olga / Maerle, Artem / Shatilov, Artem / Shatilova, Anastasia / Andreev, Sergey / Sergeev, Ilya / Trofimov, Dmitry / Latysheva, Tatyana / Ilyna, Natalia / Martynov, Alexander / Rabdano, Sevastyan / Ruzanova, Ellina / Savelev, Nikita / Pletiukhina, Iuliia /
    Safi, Ariana / Ratnikov, Vyacheslav / Gorelov, Viktor / Kaschenko, Viktor / Kucherenko, Natalya / Umarova, Irina / Moskaleva, Svetlana / Fabrichnikov, Sergei / Zuev, Oleg / Pavlov, Nikolai / Kruchko, Daria / Berzin, Igor / Goryachev, Dmitriy / Merkulov, Vadim / Shipulin, German / Udin, Sergey / Trukhin, Victor / Valenta, Rudolf / Skvortsova, Veronica

    Allergy

    2023  Volume 78, Issue 6, Page(s) 1639–1653

    Abstract: Background: Severe acute respiratory syndrome corona virus (SARS-CoV-2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS-CoV-2-specific siRNA- ... ...

    Abstract Background: Severe acute respiratory syndrome corona virus (SARS-CoV-2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS-CoV-2-specific siRNA-peptide dendrimer formulation MIR 19® (siR-7-EM/KK-46) targeting a conserved sequence in known SARS-CoV-2 variants for treatment of COVID-19.
    Methods: We conducted an open-label, randomized, controlled multicenter phase II trial (NCT05184127) evaluating safety and efficacy of inhaled siR-7-EM/KK-46 (3.7 mg and 11.1 mg/day: low and high dose, respectively) in comparison with standard etiotropic drug treatment (control group) in patients hospitalized with moderate COVID-19 (N = 52 for each group). The primary endpoint was the time to clinical improvement according to predefined criteria within 14 days of randomization.
    Results: Patients from the low-dose group achieved the primary endpoint defined by simultaneous achievement of relief of fever, normalization of respiratory rate, reduction of coughing, and oxygen saturation of >95% for 48 h significantly earlier (median 6 days; 95% confidence interval [CI]: 5-7, HR 1.75, p = .0005) than patients from the control group (8 days; 95% CI: 7-10). No significant clinical efficacy was observed for the high-dose group. Adverse events were reported in 26 (50.00%), 25 (48.08%), and 28 (53.85%) patients from the low-, high-dose and control group, respectively. None of them were associated with siR-7-EM/KK-46.
    Conclusions: siR-7-EM/KK-46, a SARS-CoV-2-specific siRNA-peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID-19 compared to standard therapy in a randomized controlled trial.
    MeSH term(s) Humans ; COVID-19 ; SARS-CoV-2 ; Dendrimers ; RNA, Small Interfering ; Treatment Outcome ; Peptides/therapeutic use
    Chemical Substances Dendrimers ; RNA, Small Interfering ; Peptides
    Language English
    Publishing date 2023-02-14
    Publishing country Denmark
    Document type Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.15663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Malignant fibrous histiocytoma of the lower lip

    Pechalova Petia F / Poriazova Elena G. / Pavlov Nikolai V / Anavi Benjamin L.

    Sanamed, Vol 7, Iss 1, Pp 27-

    A case report

    2012  Volume 30

    Abstract: Malignant fibrous histiocytoma (MFH) represents the diagnosis that is still commonly used by both patients and physicians although in 2002., the World Health Organization (WHO) declassified MFH as a formal diagnostic entity, renaming it as an ... ...

    Abstract Malignant fibrous histiocytoma (MFH) represents the diagnosis that is still commonly used by both patients and physicians although in 2002., the World Health Organization (WHO) declassified MFH as a formal diagnostic entity, renaming it as an undifferentiated pleomorphic sarcoma not specifying it further. MFH is extremely rare in the oral cavity. The aim of this article was to describe a newly diagnosed case of primary MFH in a 78-year-old male presented after 4-months history of rapidly increasing swelling of lower lip. Histopathology of the lesion showed highly malignant cell infiltration with epithelioid/spindle cell type morphology. Immunohistochemical study was positive for vimentin (++), S-100 protein (++) and negative for desmin and cytokeratin. The authors discussed the possibilities of immunohistochemical study and necessity of individual treatment plan in patients with MFH, comparing their point of view with other studies.
    Keywords malignant fibrous histiocytoma ; undifferentiated pleomorphic sarcoma ; oral cavity ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2012-03-01T00:00:00Z
    Publisher Association of medical doctors Sanamed Novi Pazar
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Malignant fibrous histiocytoma of the lower lip

    Pechalova Petia F / Poriazova Elena G / Pavlov Nikolai V / Anavi Benjamin L.

    Sanamed, Vol 7, Iss 1, Pp 27-

    A case report

    2012  Volume 30

    Abstract: Malignant fibrous histiocytoma (MFH) represents the diagnosis that is still commonly used by both patients and physicians although in 2002., the World Health Organization (WHO) declassified MFH as a formal diagnostic entity, renaming it as an ... ...

    Abstract Malignant fibrous histiocytoma (MFH) represents the diagnosis that is still commonly used by both patients and physicians although in 2002., the World Health Organization (WHO) declassified MFH as a formal diagnostic entity, renaming it as an undifferentiated pleomorphic sarcoma not specifying it further. MFH is extremely rare in the oral cavity. The aim of this article was to describe a newly diagnosed case of primary MFH in a 78-year-old male presented after 4-months history of rapidly increasing swelling of lower lip. Histopathology of the lesion showed highly malignant cell infiltration with epithelioid/spindle cell type morphology. Immunohistochemical study was positive for vimentin (++), S-100 protein (++) and negative for desmin and cytokeratin. The authors discussed the possibilities of immunohistochemical study and necessity of individual treatment plan in patients with MFH, comparing their point of view with other studies.
    Keywords malignant fibrous histiocytoma ; undifferentiated pleomorphic sarcoma ; oral cavity ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2012-01-01T00:00:00Z
    Publisher Association of medical doctors Sanamed Novi Pazar
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Book: Die deutsche Vereinigung aus sowjet-russischer Perspektive

    Pavlov, Nikolai

    ein Bericht zur Lösung der deutschen Frage, versehen mit Kommentaren und historischen Rückblicken

    1996  

    Author's details Nikolai Pawlow
    Keywords Wiedervereinigung ; Deutsche Frage ; Sowjetunion
    Language German
    Size 260 S
    Publisher Lang
    Publishing place Frankfurt am Main u.a.
    Document type Book
    Note Literaturverz. S. 253 - 260
    ISBN 3631489056 ; 9783631489055
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  10. Book: Die deutsche Vereinigung aus sowjet-russischer Perspektive

    Pavlov, Nikolai

    ein Bericht zur Lösung der deutschen Frage, versehen mit Kommentaren und historischen Rückblicken

    1996  

    Author's details Nikolai Pawlow
    Keywords Wiedervereinigung ; Deutsche Frage ; Sowjetunion
    Language German
    Size 260 S
    Publisher Lang
    Publishing place Frankfurt am Main u.a.
    Document type Book
    Note Literaturverz. S. 253 - 260
    ISBN 3631489056 ; 9783631489055
    Database Library catalogue of the German National Library of Science and Technology (TIB), Hannover

    More links

    Kategorien

To top